Product Description
Mechanisms of Action: Proton Pump Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Indonesia | Mexico | Philippines
Approved Indications: None
Known Adverse Events: None
Company: HK inno.N
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Korea
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Duodenal Ulcer|Helicobacter Infections|Peptic Ulcer
Phase 1: Esophagitis|Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IN_APA_E02 | P2 |
Recruiting |
Helicobacter Infections |
2024-12-31 |
24% |
| IN_APA_123 | P1 |
Not yet recruiting |
Healthy Volunteers |
2024-11-01 |
70% |
| IN_APA_124 | P1 |
Enrolling by invitation |
Healthy Volunteers |
2024-07-31 |
28% |
| IN_APA_308 | P3 |
Recruiting |
Peptic Ulcer |
2024-06-01 |
33% |